Immune Design Corp. | Ownership
Companies that own Immune Design Corp.
Ecor1 Capital LLC
4,437,600
9.21%
0
1.75%
06/30/2018
BVF Partners LP
4,158,353
8.63%
52,153
1.07%
06/30/2018
BlackRock Fund Advisors
1,887,829
3.92%
175,711
0%
06/30/2018
The Vanguard Group, Inc.
1,568,567
3.26%
34,851
0%
06/30/2018
Bain Capital Public Equity LP
1,221,368
2.54%
-459,619
0.28%
06/30/2018
Fidelity Management & Research Co.
1,184,492
2.46%
0
0%
06/30/2018
SSgA Funds Management, Inc.
466,159
0.97%
73,326
0%
06/30/2018
Dimensional Fund Advisors LP
447,026
0.93%
254,696
0%
06/30/2018
Portolan Capital Management LLC
444,875
0.92%
444,875
0.16%
06/30/2018
PanAgora Asset Management, Inc.
408,067
0.85%
14,120
0.01%
06/30/2018
| Address |
1616 Eastlake Avenue East
Seattle Washington 98102
United States
|
|
Employees
|
- |
| Website |
http://www.immunedesign.com |
| Updated |
09/14/2018 |
| Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. |
